We are analyzing https://link.springer.com/article/10.1007/s10549-007-9645-1.

Title:
Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer | Breast Cancer Research and Treatment
Description:
The epidermal growth factor receptor (EGFR) and the estrogen receptor (ER) modulator Amplified In Breast cancer-1 (AIB1) have been reported to be of importance for the prognosis of breast cancer patients. We have analyzed AIB1 and EGFR by immunohistochemistry in primary breast cancers (n = 297) arranged in a tissue microarray in order to predict outcome after adjuvant endocrine therapy with tamoxifen for two years. High expression of AIB1 was associated with DNA-nondiploidy, high S-phase fraction, HER2 amplification, and short term (≤2 years) distant disease-free survival (DDFS), independent of ER status. High expression of EGFR was strongly associated to ER negativity and also correlated with progesterone receptor negativity, high S-phase fraction, and inversely correlated with nodal metastases. In univariate analysis, high EGFR was associated with shorter DDFS (hazard ratio 2.1; P = 0.017), and reached borderline significance in a multivariate analysis, adjusting for ER, menopausal and lymph node status, tumor size, and HER2 (P = 0.057). In conclusion, both AIB1 and EGFR were associated to DDFS for breast cancer patients treated with two years of adjuvant tamoxifen; AIB1 with the development of early distant recurrences, indicating association between high AIB1 and resistance to tamoxifen during treatment, and EGFR with distant recurrences up to a follow up of five years.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't see how the site brings in money.

While profit motivates many websites, others exist to inspire, entertain, or provide valuable resources. Websites have a variety of goals. And this might be one of them. Link.springer.com has a secret sauce for making money, but we can't detect it yet.

Keywords {🔍}

cancer, breast, article, google, scholar, receptor, cas, pubmed, tamoxifen, growth, factor, estrogen, aib, egfr, adjuvant, clin, epidermal, patients, res, therapy, expression, research, clinical, endocrine, resistance, lund, years, high, early, access, oncol, privacy, cookies, content, fernö, trial, receptorpositive, suppl, osborne, university, data, publish, search, treatment, amplified, predicting, bendahl, prognosis, primary, distant,

Topics {✒️}

primary breast cancers month download article/chapter node-negative breast caner steroid hormone receptors hormone receptor-positive growth factor pathways early breast cancer high s-phase fraction distant disease-free survival human breast cancer swedish research council postmenopausal breast cancer breast cancer cells swedish cancer society early distant recurrences breast cancer patients estrogen receptor–positive full article pdf breast cancer samples privacy choices/manage cookies erbb-2 signaling activity estrogen receptor status progesterone receptor negativity lund research foundation lymph node status potentially predictive markers elisabeth nilsson foundation adjuvant s-1 therapy european economic area semi-quantitative scoring overcoming endocrine resistance breast cancer breast cancer-1 breast cancer 1 conditions privacy policy article dihge twenty-year results endocrine therapy resistance steroid receptors reached borderline significance predicting clinical outcome pär-ola bendahl check access instant access accepting optional cookies adjuvant endocrine therapy tamoxifen response adjuvant tamoxifen therapy year median follow mårten fernö

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer
         description:The epidermal growth factor receptor (EGFR) and the estrogen receptor (ER) modulator Amplified In Breast cancer-1 (AIB1) have been reported to be of importance for the prognosis of breast cancer patients. We have analyzed AIB1 and EGFR by immunohistochemistry in primary breast cancers (n = 297) arranged in a tissue microarray in order to predict outcome after adjuvant endocrine therapy with tamoxifen for two years. High expression of AIB1 was associated with DNA-nondiploidy, high S-phase fraction, HER2 amplification, and short term (≤2 years) distant disease-free survival (DDFS), independent of ER status. High expression of EGFR was strongly associated to ER negativity and also correlated with progesterone receptor negativity, high S-phase fraction, and inversely correlated with nodal metastases. In univariate analysis, high EGFR was associated with shorter DDFS (hazard ratio 2.1; P = 0.017), and reached borderline significance in a multivariate analysis, adjusting for ER, menopausal and lymph node status, tumor size, and HER2 (P = 0.057). In conclusion, both AIB1 and EGFR were associated to DDFS for breast cancer patients treated with two years of adjuvant tamoxifen; AIB1 with the development of early distant recurrences, indicating association between high AIB1 and resistance to tamoxifen during treatment, and EGFR with distant recurrences up to a follow up of five years.
         datePublished:2007-07-17T00:00:00Z
         dateModified:2007-07-17T00:00:00Z
         pageStart:255
         pageEnd:262
         sameAs:https://doi.org/10.1007/s10549-007-9645-1
         keywords:
            AIB1
            Breast cancer
            EGFR
            Prognosis
            Resistance
            Tamoxifen
            Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-007-9645-1/MediaObjects/10549_2007_9645_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-007-9645-1/MediaObjects/10549_2007_9645_Fig2_HTML.gif
         isPartOf:
            name:Breast Cancer Research and Treatment
            issn:
               1573-7217
               0167-6806
            volumeNumber:109
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Looket Dihge
               affiliation:
                     name:University of Lund
                     address:
                        name:Department of Oncology, Clinical Sciences, University of Lund, Lund, Sweden
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Pär-Ola Bendahl
               affiliation:
                     name:University of Lund
                     address:
                        name:Department of Oncology, Clinical Sciences, University of Lund, Lund, Sweden
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Dorthe Grabau
               affiliation:
                     name: University of Lund
                     address:
                        name:Department of Pathology, Clinical Sciences, University of Lund, Lund, Sweden
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jorma Isola
               affiliation:
                     name:University of Tampere
                     address:
                        name:Institute of Medical Technology, University of Tampere, Tampere, Finland
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Kristina Lövgren
               affiliation:
                     name:University of Lund
                     address:
                        name:Department of Oncology, Clinical Sciences, University of Lund, Lund, Sweden
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Lisa Rydén
               affiliation:
                     name:University of Lund
                     address:
                        name:Department of Surgery, Clinical Sciences, University of Lund, Lund, Sweden
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Mårten Fernö
               affiliation:
                     name:University of Lund
                     address:
                        name:Department of Oncology, Clinical Sciences, University of Lund, Lund, Sweden
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer
      description:The epidermal growth factor receptor (EGFR) and the estrogen receptor (ER) modulator Amplified In Breast cancer-1 (AIB1) have been reported to be of importance for the prognosis of breast cancer patients. We have analyzed AIB1 and EGFR by immunohistochemistry in primary breast cancers (n = 297) arranged in a tissue microarray in order to predict outcome after adjuvant endocrine therapy with tamoxifen for two years. High expression of AIB1 was associated with DNA-nondiploidy, high S-phase fraction, HER2 amplification, and short term (≤2 years) distant disease-free survival (DDFS), independent of ER status. High expression of EGFR was strongly associated to ER negativity and also correlated with progesterone receptor negativity, high S-phase fraction, and inversely correlated with nodal metastases. In univariate analysis, high EGFR was associated with shorter DDFS (hazard ratio 2.1; P = 0.017), and reached borderline significance in a multivariate analysis, adjusting for ER, menopausal and lymph node status, tumor size, and HER2 (P = 0.057). In conclusion, both AIB1 and EGFR were associated to DDFS for breast cancer patients treated with two years of adjuvant tamoxifen; AIB1 with the development of early distant recurrences, indicating association between high AIB1 and resistance to tamoxifen during treatment, and EGFR with distant recurrences up to a follow up of five years.
      datePublished:2007-07-17T00:00:00Z
      dateModified:2007-07-17T00:00:00Z
      pageStart:255
      pageEnd:262
      sameAs:https://doi.org/10.1007/s10549-007-9645-1
      keywords:
         AIB1
         Breast cancer
         EGFR
         Prognosis
         Resistance
         Tamoxifen
         Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-007-9645-1/MediaObjects/10549_2007_9645_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-007-9645-1/MediaObjects/10549_2007_9645_Fig2_HTML.gif
      isPartOf:
         name:Breast Cancer Research and Treatment
         issn:
            1573-7217
            0167-6806
         volumeNumber:109
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Looket Dihge
            affiliation:
                  name:University of Lund
                  address:
                     name:Department of Oncology, Clinical Sciences, University of Lund, Lund, Sweden
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Pär-Ola Bendahl
            affiliation:
                  name:University of Lund
                  address:
                     name:Department of Oncology, Clinical Sciences, University of Lund, Lund, Sweden
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Dorthe Grabau
            affiliation:
                  name: University of Lund
                  address:
                     name:Department of Pathology, Clinical Sciences, University of Lund, Lund, Sweden
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jorma Isola
            affiliation:
                  name:University of Tampere
                  address:
                     name:Institute of Medical Technology, University of Tampere, Tampere, Finland
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Kristina Lövgren
            affiliation:
                  name:University of Lund
                  address:
                     name:Department of Oncology, Clinical Sciences, University of Lund, Lund, Sweden
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Lisa Rydén
            affiliation:
                  name:University of Lund
                  address:
                     name:Department of Surgery, Clinical Sciences, University of Lund, Lund, Sweden
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Mårten Fernö
            affiliation:
                  name:University of Lund
                  address:
                     name:Department of Oncology, Clinical Sciences, University of Lund, Lund, Sweden
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research and Treatment
      issn:
         1573-7217
         0167-6806
      volumeNumber:109
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Lund
      address:
         name:Department of Oncology, Clinical Sciences, University of Lund, Lund, Sweden
         type:PostalAddress
      name:University of Lund
      address:
         name:Department of Oncology, Clinical Sciences, University of Lund, Lund, Sweden
         type:PostalAddress
      name: University of Lund
      address:
         name:Department of Pathology, Clinical Sciences, University of Lund, Lund, Sweden
         type:PostalAddress
      name:University of Tampere
      address:
         name:Institute of Medical Technology, University of Tampere, Tampere, Finland
         type:PostalAddress
      name:University of Lund
      address:
         name:Department of Oncology, Clinical Sciences, University of Lund, Lund, Sweden
         type:PostalAddress
      name:University of Lund
      address:
         name:Department of Surgery, Clinical Sciences, University of Lund, Lund, Sweden
         type:PostalAddress
      name:University of Lund
      address:
         name:Department of Oncology, Clinical Sciences, University of Lund, Lund, Sweden
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Looket Dihge
      affiliation:
            name:University of Lund
            address:
               name:Department of Oncology, Clinical Sciences, University of Lund, Lund, Sweden
               type:PostalAddress
            type:Organization
      name:Pär-Ola Bendahl
      affiliation:
            name:University of Lund
            address:
               name:Department of Oncology, Clinical Sciences, University of Lund, Lund, Sweden
               type:PostalAddress
            type:Organization
      name:Dorthe Grabau
      affiliation:
            name: University of Lund
            address:
               name:Department of Pathology, Clinical Sciences, University of Lund, Lund, Sweden
               type:PostalAddress
            type:Organization
      name:Jorma Isola
      affiliation:
            name:University of Tampere
            address:
               name:Institute of Medical Technology, University of Tampere, Tampere, Finland
               type:PostalAddress
            type:Organization
      name:Kristina Lövgren
      affiliation:
            name:University of Lund
            address:
               name:Department of Oncology, Clinical Sciences, University of Lund, Lund, Sweden
               type:PostalAddress
            type:Organization
      name:Lisa Rydén
      affiliation:
            name:University of Lund
            address:
               name:Department of Surgery, Clinical Sciences, University of Lund, Lund, Sweden
               type:PostalAddress
            type:Organization
      name:Mårten Fernö
      affiliation:
            name:University of Lund
            address:
               name:Department of Oncology, Clinical Sciences, University of Lund, Lund, Sweden
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Oncology, Clinical Sciences, University of Lund, Lund, Sweden
      name:Department of Oncology, Clinical Sciences, University of Lund, Lund, Sweden
      name:Department of Pathology, Clinical Sciences, University of Lund, Lund, Sweden
      name:Institute of Medical Technology, University of Tampere, Tampere, Finland
      name:Department of Oncology, Clinical Sciences, University of Lund, Lund, Sweden
      name:Department of Surgery, Clinical Sciences, University of Lund, Lund, Sweden
      name:Department of Oncology, Clinical Sciences, University of Lund, Lund, Sweden
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(103)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Foundation
Prism.js

CDN Services {📦}

Crossref

4.48s.

LINK . SPRINGER . COM {}